Innoventric

Company Overview

Snapshot

Founded in February 2016 by Amir Danino, David Planer, and Rafi Benary, Innoventric operates with 11–50 employees. The company has raised $42.5M across 4 funding rounds from 6 investors. In October 2024, Innoventric secured a B Round of funding, led by RA Capital Management.

Business overview

Innoventric is a structural heart medical device company focused on developing percutaneous solutions for tricuspid regurgitation and right heart disease. The company's core product is an easily deployable percutaneous functional tricuspid valve replacement, Trillium, which utilizes cross-caval anchoring and an innovative multi-valve design for long-lasting blood flow regulation. Innoventric aims to significantly improve the quality of life and lifespan for patients with structural heart disease, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers in geomarkets such as Europe and the United States.

Strategic signal

In October 2024, Innoventric secured a B Round of funding, led by RA Capital Management. This investment highlights continued investor confidence in the company's innovative transcatheter solutions for tricuspid regurgitation, signaling strong potential for advancing medical device technology and reducing the need for traditional surgical valve replacement.

Company Intelligence Q&A

What is Innoventric's primary focus?

Innoventric is primarily engaged in the development of percutaneous solutions for tricuspid regurgitation and right heart disease, aiming to improve the quality of life and lifespan of patients with structural heart disease.

When was Innoventric founded and by whom?

Innoventric was founded in February 2016 by Amir Danino, David Planer, and Rafi Benary.

What significant funding did Innoventric receive in October 2024?

In October 2024, Innoventric secured a B Round of funding, led by RA Capital Management, to reduce the medical need for surgical valve replacement and general anesthesia.

What was a key milestone for Innoventric in November 2021?

In November 2021, Innoventric won the prestigious Horizon Europe Grant and secured a Series A investment from investors including.

What is the name of Innoventric's main product?

Innoventric's main product is Trillium, a percutaneous functional tricuspid valve replacement designed for long-lasting blood flow regulation.